Friday, May 23, 2008 - 18:30

Innate Pharma SA today announces results for its Phase IIa study with IPH 1101, an agonist of gamma delta T cells, as a second line monotherapy in metastatic renal cell carcinoma.
In connection with this announcement, a conference call was organized on May 23, 2008.   

The slideshow is available here:

AttachmentSize
PR in english120.39 KB
CP en français123.6 KB